Home > Analytics > GLAND PHARMA

GLAND PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 543245     NSE : GLAND    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward
Pledged Shares : NA
Sep 30,2022
Price(EOD): ₹ 2,095.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 34,509.59 Cr
Value of ₹ 1 Lac invested in GLAND PHARMA
on Nov 20,2020 (price: ₹ 1,820.45)

₹ 1 L

₹ 1.15 L

1W : 1.5% 1M : -16.4% 1Y : -43.2%
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results
GLAND PHARMA is part of below Screeners ↓
Top Undervalued Large Cap Stocks
Industry Peers & Returns1W1M1Y
GLAND PHARMA 1.5% -16.4% -43.2%
SUN PHARMACEUTICAL INDUSTRIES 5.8% 8.9% 19.4%
DIVIS LABORATORIES 0.4% 2.4% -27.6%
DR REDDYS LABORATORIES 4.9% 3.1% -9.1%
CIPLA 4.7% 9% 14.9%
PIRAMAL ENTERPRISES -2.9% -16% -68.6%
CADILA HEALTHCARE 8.6% 3.8% -29.6%
TORRENT PHARMACEUTICALS 3% 1.5% -0.4%
ALKEM LABORATORIES -0.4% 10.9% -17.4%

FUNDAMENTAL ANALYSIS OF GLAND PHARMA

 
Fundamentals Score
[ Q(TTM): Jun2022, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF GLAND PHARMA

 
Valuation Score
[As on : Sep 30,2022 ]

Ratio Consolidated
P/E
P/B
P/S
31.65
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,090.18 Cr
[Latest Qtr - Jun2022 - Consolidated Results ]

4.83
P/B Calculated based on Book Value of Rs 7,144.38 Cr
[Latest Year - Mar2022 - Consolidated Results ]

8.41
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,103.71 Cr
[Latest Qtr - Jun2022 - Consolidated Results ]

Financial Ratios →

Insights 💡 GLAND is one of the potential top 17% undervalued companies ! Discover More →

FAIR VALUE OF GLAND PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-15%
-23%
-23%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF GLAND PHARMA



GLAND PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF GLAND PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0
0
0
-
0
0
0
-
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF GLAND PHARMA

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF GLAND PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-22.31%
-22.52%
-18.92%
-19.84%
-25.74%
-38.13%
-34.62%
-34.64%
QtrlyTrend
-8
Latest Qtr: Jun2022
Quarterly Result Analysis →


GLAND PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 1.8% 1.4% -9.9%
S&P BSE MIDCAP SELECT INDEX -1.4% -1.5% -1.8%
S&P BSE MIDSMALLCAP -1.5% -1.4% 0.2%
S&P BSE 500 -1.5% -3.3% -2.2%
S&P BSE 250 LARGEMIDCAP -1.6% -3.5% -2.3%
NSE Indices1W1M1Y
NIFTY PHARMA 2.9% 2.2% -8.4%
NIFTY HEALTHCARE 2.7% 2.5% -7.6%
NIFTY MNC -0.8% -0.3% 2.1%
NIFTY500 MULTICAP 50:25:25 -1.4% -2.5% -1.2%
NIFTY LARGE MIDCAP 250 -1.5% -2.8% -0.1%

You may also like the below Video Courses


FAQ about GLAND PHARMA


Is GLAND PHARMA good for long term investment?

As on Sep 30,2022, the Fundamentals of GLAND PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of GLAND PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is GLAND PHARMA UnderValued or OverValued?

As on Sep 30,2022, GLAND PHARMA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of GLAND PHARMA ?

As on Sep 30,2022, the Intrinsic Value of GLAND PHARMA is Rs. 2,706.14 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 2,471.23
Fair Value [Median EV / Sales Model] : Rs. 2,706.14
Fair Value [Median Price / Sales Model] : Rs. 2,706.88
Estimated Median Fair Value of GLAND PHARMA : Rs. 2,706.14

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is GLAND PHARMA trading at a Premium or Discount?

As on Sep 30,2022, GLAND PHARMA is trading at a Discount of -23% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].